Preclinical Research Leader, SURPASS Receives CRO Leadership Awards by Life Science Leader Magazine for a Second Year in a Row.
OSCEOLA, Wis. and MOUNTAIN VIEW, Calif., May 13, 2015 /PRNewswire-iReach/ — Surpass, Inc. (“Surpass”), a recognized leader in preclinical research services for the medical device, pharma, and biotech industries, has been acknowledged for excellence in the areas of quality and regulatory by Life Science Leader Magazine. This is the second year in a row that Surpass has received CRO Leadership Award recognition. The awards are based on industry research conducted by Nice Insight which includes feedback from customers that use preclinical contract research organization (CRO) services.
“We are honored to be recognized again this year as a leading preclinical contract research organization with impeccable quality and regulatory compliance,” said Surpass CEO, Dr. Tim Pelura. “These awards acknowledge Surpass’ strong commitment to excellence and delivering robust preclinical data to our clients. As an active member of the medical innovation continuum, we bring more to our client partners, consistently delivering high quality translational data and innovative solutions to help our clients advance their technologies and therapies into the marketplace.”
“These awards were developed to assist life science executives and directors in their vetting process of CROs. The surveys and industry research for this award is managed by Nice Insight, the market research division of That’s Nice LLC. Nice Insight conducts an annual survey to collect baseline customer awareness and customer perception of 100+ CMOs and 70+ CROs. The annual survey includes 250+ questions and is heavily logic based so that the right respondents are asked the right questions.” Ed Miseta, executive editor, Life Science Leader Magazine. More than 2300 decision makers who use CRO services were asked their perceptions of industry CROs. From all CROs profiled, the top 10% in each category were recognized with CRO Leadership Awards. A full list of 2015 winners can be found on the CRO Leadership Awards website.
At Surpass, our innovative approach to preclinical research goes beyond the ordinary. We’re changing the rules for a better way to get from concept to reality.
Surpass is a trusted preclinical contract research organization with extensive experience conducting medical device, pharmaceutical, biotech and combination product studies with specialized expertise in surgical and interventional procedures. Our preclinical testing services in large in vivo models and human cadavers span the product development cycle (proof-of-concept, early feasibility, iterative prototype evaluations, human factors assessments, validation, pharmacokinetics (PK), GLP/safety studies, and physician/clinical bio-skills training).
At Surpass, we bring more to our client partners. Our award-winning Research Team provides insightful solutions and assistance every step of the way, offering expert advice and the level of comprehensive support needed to make your study successful – the first time.
Surpass’ breadth of case experience in preclinical studies includes feasibility and safety assessments of ablation systems, wound healing therapies, vascular grafts, orthopedic prostheses, stents, closure devices, valves, infusion pumps, drug coated balloons, neurostimulators, renal denervation systems, dermal patches, imaging systems, cardiac assist devices, and much more. Whether you are a startup or an established player, Surpass is uniquely qualified to make your study successful. Contact Surpass today at (715) 294-4371( Greater Twin Cities) or (650) 938-3675 (Silicon Valley).
Media Contact: Denise Forkey, Surpass, Inc., 650-938-2101, email@example.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Surpass, Inc.